Enhancing Electronic Health Record Data Quality

By Michael Awood

September 6, 2023

Electronic Health Record (EHR) data in biomedical research has seen a significant surge, especially during the COVID-19 pandemic. These rich data records are perfect for complex analyses, including machine learning and artificial intelligence. However, the quality of this data has drawn much concern.

Despite the critical role EHR data plays in healthcare and its frequent use in biomedical research, its quality is often overlooked. This presents a need for a standardised approach to evaluate EHR data quality.

In 1996, Wang and Strong proposed a data quality framework that covered intrinsic, contextual, representational, and accessible data quality. They highlighted that poor data quality could have social and economic impacts. Although their study was not healthcare-specific, their framework focused on the needs of data users, providing a unique perspective.

A 2013 review identified five aspects of EHR data quality – completeness, correctness, concordance, plausibility, and currency. They evaluated these aspects through seven methods, including a gold standard comparison and data element agreement. However, the definitions of these methods and dimensions often overlapped, indicating the need for a more standardised approach. Other data quality frameworks have been suggested, but they differ in their recording and discussion methods. This shows a lack of consensus and adoption.

The development of automated tools for data quality assessment holds the potential to address the data quality challenge. These tools could streamline the process and enhance efficiency. The article suggests that future research should aim at creating tools that improve data integrity and reliability in patient care and research. The potential impact of this work is vast, with implications for disease tracking, patient care, and the advancement of medical science.

It is important that EHRs reflect true and accurate data to minimise potential downstream inefficiencies – due to poor data. This data also feeds into prediction analytics or algorithms for various AI systems, where poor data could result in incorrect analytics and poor outcomes. At present, there are numerous entry points to an EHR due to the multitude of records. Data sources include researchers, medical providers, and increasingly, patients through patient-reported outcome measures (PROMs). Utilising the framework by Wang and Strong could provide a better understanding of data needs, leading to improved health records and health information exchanges (HIEs).

Reference url

Recent Posts

Opdivo lung cancer approval
           

FDA’s Opdivo Lung Cancer Approval

🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!

Learn more about this advancement and its implications for patients.

#SyenzaNews #CancerCare #FDAApproval

Mental Healthcare for Youth
                   

Mental Healthcare for Youth: Addressing Substance Use and Chronic Conditions

🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness

elacestrant breast cancer therapy
         

NICE Collaborates with Menarini to Evaluate Elacestrant Breast Cancer Treatment

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.

Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.

#SyenzaNews #BreastCancer #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.